Need professional-grade analysis? Visit stockanalysis.com
$323.54M
N/A
N/A
N/A
Northwest Biotherapeutics Inc (NWBO) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $0.20, down 0.45% from the previous close.
Over the past year, NWBO has traded between a low of $0.20 and a high of $0.36. The stock has lost 31.0% over this period. It is currently 44.4% below its 52-week high.
Northwest Biotherapeutics Inc has a market capitalization of $323.54M.
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Side-by-side comparison against top Healthcare peers.